13F Holdings
中文EN

TNGX Tango Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1819133 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY121.5%
TTM net income YoY15.0%
TTM EPS YoY36.4%
Revenue 3-yr CAGR16.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-253.4%
Net margin-229.9%
FCF margin-268.1%
EBITDA margin-249.8%

Returns

ROE-21.3%
ROA-18.9%
ROIC (approx.)-28.5%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets4.6%
Debt / equity0.00x
Current ratio50.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$62.38M$42.07M$36.53M$24.86M$37.04M
R&D expense$132.16M$143.92M$115.20M$105.91M$77.64M
SG&A expense$41.51M$43.75M$35.50M$30.02M$17.60M
Operating income-$111.29M-$145.59M-$114.17M-$111.07M-$58.19M
Pretax income-$101.59M-$130.09M-$101.61M-$108.12M-$57.94M
Income tax$4,000$208,000$134,000$54,000$292,000
Net income-$101.59M-$130.30M-$101.74M-$108.18M-$58.23M
EBITDA-$109.01M-$143.10M-$111.76M-$109.46M-$57.29M
EPS (basic)-0.87-1.19-1.08-1.23-0.94
EPS (diluted)-0.87-1.19-1.08-1.23-0.94
Weighted avg. shares (diluted)116.17M109.23M94.57M87.82M62.11M
Banking
Net interest income$5.63M$7.89M$6.62M$1.46M$495,000
Balance sheet
Cash & equivalents$112.28M$69.53M$66.39M$59.97M$142.75M
Short-term investments$230.86M$188.39M$270.50M$306.17M$342.51M
Receivables———$2.00M$2.00M
Current assets$353.76M$266.34M$346.54M$375.27M$492.34M
PP&E, net$6.87M$8.10M$9.91M$10.88M$4.83M
Total assets$398.69M$316.49M$402.57M$436.47M$500.15M
Current liabilities$21.68M$38.17M$45.94M$55.55M$40.69M
Total liabilities$52.51M$116.97M$149.46M$186.99M$155.41M
Shareholders' equity$346.18M$199.52M$253.11M$249.48M$344.75M
Shares outstanding135.94M107.73M102.20M88.18M87.60M
Cash flow statement
Operating cash flow-$138.89M-$131.50M-$117.98M-$109.08M-$59.53M
Capital expenditure$1.05M$754,000$1.53M$7.69M$1.84M
Free cash flow-$139.93M-$132.25M-$119.51M-$116.77M-$61.36M
Investing cash flow-$40.87M$86.13M$41.43M$26.40M-$183.43M
Financing cash flow$222.50M$47.66M$82.41M$1.61M$357.32M
Depreciation & amortization$2.28M$2.50M$2.42M$1.61M$897,000
Stock-based compensation$26.43M$28.90M$19.08M$14.23M$7.83M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.